Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del
Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del
About this item
Full title
Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del
Author / Creator
Publisher
United States: Massachusetts Medical Society
Journal title
The New England journal of medicine, 2017-11, Vol.377 (21), p.2013-2023
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
Patients with homozygous Phe508del cystic fibrosis were assigned to receive combination tezacaftor–ivacaftor or placebo for 24 weeks. The combination resulted in an FEV
1
that was 4 percentage points higher and a pulmonary-exacerbation rate that was 35% lower than with placebo.
Alternative Titles
Full title
Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1967858941
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1967858941
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1709846
